Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134461 | 1.00 | HRH3 (0.33) | HRH3CYP2D6OPRM1OPRL1TP53BP1 | |
| SCHEMBL1134462 | 1.00 | HRH3 (0.33) | HRH3CYP2D6OPRM1OPRL1TP53BP1 | |
| SCHEMBL13618243 | 0.90 | OPRM1 (0.35) | HRH3CYP2D6OPRM1OPRL1OPRK1 | |
| SCHEMBL1134373 | 0.90 | OPRM1 (0.35) | HRH3CYP2D6OPRM1OPRL1OPRK1 | |
| SCHEMBL1134374 | 0.90 | OPRM1 (0.35) | HRH3CYP2D6OPRM1OPRL1OPRK1 | |
| SCHEMBL121604 | 0.82 | L3MBTL3 (0.34) | HRH3OPRM1OPRL1TP53BP1L3MBTL3 | |
| SCHEMBL1134384 | 0.80 | OPRM1 (0.33) | OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL3665053 | 0.80 | L3MBTL3 (0.33) | HRH3OPRM1OPRL1TP53BP1L3MBTL3 | |
| SCHEMBL1134389 | 0.78 | PARP15 (0.31) | — | |
| SCHEMBL7088182 | 0.76 | OPRL1 (0.52) | OPRM1OPRL1OPRK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009136850-A1 | MUSCARINIC RECEPTOR AGONITS USEFUL IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | HRH3 472/4885CYP2D6 436/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.